( ectives intentions andexpectations. T...)Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference,Health

ectives, intentions and expectations. These forward-looking statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of these forward-looking statements. Actual results or developments may be materially different from the results projected or implied in these forward-looking statements. Factors that could affect our actual results include, but are not limited to, the risk of clinical results not advancing into therapeutic benefit, our ability to obtain, maintain and protect our intellectual property, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and whether regulatory or institutional approvals can be obtained and maintained, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2006 as updated in its Form 10-Q for the quarter ended March 31, 2007. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change these expectations.

Investor and Media Contact:

Stacie D. Byars
Director, Communications
Targeted Genetics Corporation
(206) 521-7392

SOURCE: Targeted Genetics

The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.

For address modifications please inform:

Tel.: 0049 (0) 341-2 24 56-30 or info@directnews.de
press kit: http://www.directnewsroom.de" target="_b
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
7. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
8. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
9. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
10. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
11. Data From Adherexs European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies